Compare Ishares Msci Brazil ETF (EWZ) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ishares Msci Brazil ETF vs Mesoblast Limited — how do they compare? Ishares Msci Brazil ETF trades at $43.47 (market cap $11.30B), while Mesoblast Limited trades at $14.18 (market cap $1.75B). The key difference: Ishares Msci Brazil ETF is far larger — about 6.5× Mesoblast Limited's market cap, and Ishares Msci Brazil ETF is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Ishares Msci Brazil ETF for 50 Days and Mesoblast Limited for 14 Days on average.
| EWZ | MESO | |
|---|---|---|
Market Cap | $11.30B | $1.75B |
Volume | 44,036,597 | 239,027 |
Sector | Broad Market / Factor | Health |
52-Week High | $43.00 | $20.96 |
52-Week Low | $28.79 | $13.19 |
Typical Hold Time | 50 Days | 14 Days |
Enterprise Value | — | $1.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWZ, the iShares MSCI Brazil ETF, trades at $43.14, up 1.82% with strong bullish momentum from moving averages but overbought RSI signals. The ETF shows unusual options activity and institutional interest, driven by Brazil's upcoming election and commodity exposure. Recent news highlights Wall Street positioning for potential policy shifts under different election outcomes, with the fund serving as a diversification tool from U.S. tech concentration.
Outlook remains election-dependent with asymmetric upside potential through call options. Risks include political volatility, U.S.-Brazil trade tensions, and currency fluctuations. The technical setup suggests near-term consolidation near pivot points while fundamentals rely on Brazil's economic policies and commodity performance.
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ishares Msci Brazil ETF
EWZ is a country-specific ETF that tracks the Brazilian equity market. It provides exposure to large and mid-sized companies in Brazil, with a heavy focus on financials and materials, including major names like Nu Holdings, Vale, and Itaú Unibanco.
Read more on EWZ →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
